Medstar Health Research Institute — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EPOCH regimenRATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to kill cancer cells. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab followed by combination chemotherapy in treating patients who have refractory or recurrent non-Hodgkin's lymphoma.	SEP	Phase 2	À vérifier	United States	À vérifier
SargramostimThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer, SEP	Phase 2	Immunomodulation	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Rituximab	SEP	Phase 2	NCT00006669	Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma	WITHDRAWN

Publications

5

Molécule	Indication / population	Titre	Journal	Date
Sargramostim		Comorbidity of autoimmune diseases in patients with autoimmune pulmonary alveolar proteinosis.	Respiratory investigation
Sargramostim		Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.	Neurodegenerative disease management
Sargramostim		Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.	International journal of clinical oncology
Sargramostim		Diagnostic and Therapeutic Dilemmas in Recurrent Pulmonary Alveolar Proteinosis After Bilateral Lung Transplantation.	Respirology case reports
Sargramostim		A Marked Improvement in Mild but Progressive Autoimmune Pulmonary Alveolar Proteinosis Treated with Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy: A Case Report.	Internal medicine (Tokyo, Japan)